Ionic hydrogenation of C-20, 22-ketene dithioacetal: stereoselective synthesis of steroidal C (20R) aldehydes[†]

Bapurao B. Shingate,^{*a*} Braja G. Hazra,^{**a*} Vandana S. Pore,^{*a*} Rajesh G. Gonnade^{*b*} and Mohan M. Bhadbhade^{*b*}

 ^a Organic Chemistry Synthesis Division, National Chemical Laboratory, Pune 411 008, India. E-mail: hazra@ems.ncl.res.in; Fax: +91-20-25893153; Tel: +91-20-25893153
 ^b Center for Materials Characterization, National Chemical Laboratory, Pune 411 008, India


Received (in Cambridge, UK) 27th May 2004, Accepted 30th June 2004 First published as an Advance Article on the web 19th August 2004

Homologation of 16-dehydropregnenolone acetate 7 leads to excellent stereocontrolled synthesis of unnatural C (20R) aldehydes 4 and 6 through compound 13.

The introduction of the properly functionalized side chains onto tetracyclic steroidal starting materials has been the subject matter of several investigations.^{1,2} An important problem that arises in this approach is the stereoselective control of the C-20 stereochemistry. These efforts have been spurred by the biological significance of new natural products containing modified side chains and synthetic endeavors towards a variety of ecdysones,³ vitamin D metabolites,⁴ brassinosteroids,⁵ squalamine,⁶ and various marine steroids,⁷ with the epimeric methyl configuration at C-20.

Most of the sterols isolated from plant, marine and animal sources have the C (20R) stereochemistry as in cholesterol 1 (Fig. 1). Compounds with unnatural configuration at C-20 have attracted attention because of the interesting biological activities of these epimers⁸ and hence methods for their stereoselective synthesis are highly desirable. Tsuda et al.⁹ have isolated sargasterol from Sargassum ringgoldianum and proposed its structure as (20S)fucosterol on the basis of degradation reaction. The presence of 20-isocholesta-5, 22-dien-3β-ol in the scallop Placopecten magellanicus has been suggested¹⁰ by Idler et al. Koreeda has pointed¹¹ that 20-isocholesterol 2 with C (20S) stereochemistry showed significant in vitro inhibitory activity for the conversion of cholesterol to pregnenolone. Djerassi and co-workers have isolated¹² four sterols having C (20S) stereochemistry, from a sea pen, Ptilosarcus gurneyi and also devised methods for their synthesis. Stereocontrolled synthesis of C-20 isocholesterol has also been reported.^{11a,1}

There are several reports¹⁴ of the unsuccessful stereoselective hydrogenation of steroidal C-20, 22-ene to get a single isomer at C-20. These findings on a variety of steroids prompted us to develop a new method for setting the C (20*R*) unnatural stereochemistry in compounds **4** and **6**. Synthesis of the steroidal C-22 aldehydes **3** and **5** with C (20*S*) natural configuration has been reported.^{15,16a} On the other hand not much attention has been given to the stereocontrolled synthesis of the C-22 aldehydes **4** and **6** with the unnatural configuration at C-20. These aldehydes **4** and **6** are ideal intermediates for the construction of several naturally occurring steroids^{8–12} with unnatural stereo-centres at C-20.



† Electronic supplementary information (ESI) available: experimental details and spectral data. See http://www.rsc.org/suppdata/cc/b4/b407952c/


Epimerisation of the C-20 stereo-centre of the C-22 aldehydes led to the unnatural C-22 aldehyde in poor yield.¹² Synthesis of the C (20*R*) aldehyde as an epimeric mixture from 17-keto steroids has been reported.¹⁷

Herein, we report a highly stereoselective synthesis of the aldehydes 4 and 6 starting from 16-dehydropregnenolone acetate 7. The salient feature of this synthesis is ionic hydrogenation of C-20, 22-ketene dithioacetal to set the desired chirality at C-20 with one hundred percent stereoselectivity. Homologation of 16-dehydropregnenolone acetate 7 to C-22 aldehydes 4 and 6 with C (20*R*) unnatural configuration is reported for the first time.

16-Dehydropregnenolone acetate¹⁸ 7 was converted^{16b} to its 3β -*tert*-butyldimethylsilyl ether **8** (Scheme 1). Exposure of compound **8** to 2-lithio-1,3-dithiane furnished the C-20 *tert*-alcohol **9**. Addition of 2-lithio-1,3-dithiane to 20-keto pregnane derivatives is known¹⁹ to generate stereoselectively the C (20*R*) configuration at this centre. The stereochemistry at C-20 has been confirmed by single crystal X-ray studies.

Dehydration of the *tert*-alcohol **9** was very facile and took place with SOCl₂–pyridine in CH₂Cl₂ to furnish ketene dithioacetal **10**. Attempted reduction of compound **10** by catalytic hydrogenation with Pd–C, with Mg in methanol and with Zn in acetic acid²⁰ resulted in recovery of the starting materials.

Ionic hydrogenation of the ketene dithioacetal with



Scheme 1 Reagents and conditions: (a) 1,3-dithiane, n-BuLi, THF, -35 °C, 2 h and 0 °C for 12 h, 82%; (b) SOCl₂, pyridine, CH₂Cl₂, -5 °C, 5 min., 84%; (c) n-Bu₄NF, THF, 25 °C, 12 h, 93%; (d) Ac₂O, pyridine, DMAP, 30 °C, 3 h, 98%; (e) Et₃SiH, CF₃COOH, CH₂Cl₂, 25 °C, 18 h, 89%; (f) HgO, HgCl₂, CH₃CN, H₂O, reflux, 3 h, 96%; (g) KOH, MeOH, THF, 30 °C, 12 h, 92%; (h) *p*-toluenesulfonyl chloride, pyridine, 30 °C, 12 h, 94%; (i) MeOH, CH₃COONa, reflux, 4 h, 83%; (j) Dess–Martin periodinane, CH₃CN, CH₂Cl₂–H₂O, 30 °C, 5 h, 55%.




Fig. 2 Mechanism of ionic hydrogenation of ketene dithioacetal.




Fig. 3 $ORTEP^{23}$ view of 3 β -acetoxy-pregna-5-en-20-dithiane 13.

 3β -acetate²¹12 using triethylsilane and trifluoroacetic acid in dichloromethane afforded the compound 13. We attribute the exclusive formation of 12A by protonation of 12 from the less hindered α face (Fig. 2). This generates a sulfur-stabilised intermediate²² that then captures hydride from the Et₃SiH to give product 13. Ionic hydrogenation of compound 12 is chemoselective as the 5, 6-double bond is unaffected.

The exclusive formation of C (20*R*)-methyl compound **13** by ionic hydrogenation is confirmed by a single C-21 methyl at δ 1.05 ppm (d, J = 6 Hz) in ¹H NMR and by a single methyl signal at δ 15.84 ppm in ¹³C NMR. This was further confirmed unambiguously by single crystal X-ray analysis (Fig. 3).[‡]

Removal of the dithiane moiety of compound 13 by oxidative hydrolysis afforded the known aldehyde¹⁵ 4 (Scheme 1). Hydrolysis of the 3 β -acetate of compound 13 followed by tosylation of the resulting alcohol 14 furnished compound 15. Tosylate 15 was converted into the i-methyl ether 16. The cleavage of the dithiane moiety of 16 was carried out with Dess–Martin periodinane²⁴ to afford the known¹² aldehyde 6. Dess–Martin periodinane is the reagent of choice for the acid sensitive i-methyl ether 16.

In summary, we have achieved a highly efficient chemoselective and stereoselective method for reduction of ketene dithioacetal **12** by ionic hydrogenation to get the compound **13** with unnatural C (20R) configuration.

BBS thanks UGC for a Fellowship, and BGH thanks DST, New Delhi for financial support.

Notes and references

‡ Crystal data for **13**: C₂₇ H₄₂ O₂ S₂·0.25(C₆ H₁₂), M = 473.13, crystal dimensions 0.42 × 0.22 × 0.20 mm, crystal system: triclinic, space group *P*1, *a* = 8.1143(12), *b* = 9.7663(15), *c* = 19.215(3) Å, *α* = 99.467(2), *β* = 99.538(2), *γ* = 90.654(2) °, *V* = 1480.0(4) Å³, *Z* = 2, *D_c* = 1.062 g cm⁻³, μ (Mo–K*α*) = 0.1995 mm⁻¹, *T* = 293(2) K, 14181 reflections collected, 10151 unique [*I* > 2*σ*(*I*)], *R* value 0.0554, *wR*2 = 0.1385 (all data

R = 0.0639, wR2 = 0.1455). The crystal lattice contains two disordered cyclohexane molecules with the occupancy of 0.125 each. CCDC 240193 (compound 13) and 240194 (compound 9). See http://www.rsc.org/suppdata/cc/b4/b407952c/ for crystallographic data in .cif format.

- (a) For a review on the construction of steroid side chain, see: D. M. Piatak and J. Wicha, *Chem. Rev.*, 1978, **78**, 199; (b) J. Redpath and F. Zeelan, *Chem. Soc. Rev.*, 1983, **12**, 75.
- 2 (a) T. Ibuka, T. Taga, T. Shingi, M. Saito, S. Nishii and Y. Yamamoto, J. Org. Chem., 1988, 53, 3947; (b) Z. He, C. S. Yi and W. A. Donaldson, Org. Lett., 2003, 5, 1567 and references cited therein; (c) W. Yu and Z. Jin, J. Am. Chem. Soc., 2001, 123, 3369; (d) S. Harada, H. Kiyono, R. Nishio, T. Tagushi and Y. Hanzawa, J. Org. Chem., 1997, 62, 3994.
- 3 K. Nakanishi, Pure Appl. Chem., 1971, 25, 167.
- 4 (a) P. E. Georghiou, *Chem. Soc. Rev.*, 1977, **6**, 83; (b) E. Gorobets,
 V. Stepanenko and J. Wiche, *Eur. J. Org. Chem.*, 2004, 783;
 (c) D. F. Taber, Q. Jiang, B. Chen, W. Zhang and C. L. Campbell,
 J. Org. Chem., 2002, **67**, 4821.
- 5 (a) G. Adam and V. Marquardt, *Phytochemistry*, 1986, **25**, 1787; (b) F. A. Lokhvich, V. A. Khripach and V. N. Zhabinskii, *Russ. Chem. Rev.*, 1991, **60**, 658.
- 6 J. M. Brunel and Y. Letourneux, Eur. J. Org. Chem., 2003, 3897.
- 7 W. R. Nes and M. L. Mckean, *Biochemistry of Steroids and other Isoprenoids*, University Park Press, Baltimore, Maryland, 1977.
- 8 T. Mandai, T. Matsumoto, M. Kawada and J. Tsujii, *Tetrahedron*, 1994, 50, 475 and references cited therein.
- 9 (a) K. Tsuda, S. Akagi, Y. Kishida and R. Hayatsu, *Chem. Pharm. Bull.*, 1957, **5**, 85; (b) K. Tsuda, R. Hayatsu, Y. Kishida and S. Akagi, *J. Am. Chem. Soc.*, 1958, **80**, 921; (c) K. Tsuda, K. Sakai and N. Ikekawa, *Chem. Pharm. Bull.*, 1961, **9**, 835.
- 10 D. R. Idler, M. W. Khalil, J. D. Gilbert and C. J. W. Brooks, *Steroids*, 1976, **27**, 155.
- (a) M. Koreeda and N. Koizumi, *Tetrahedron Lett.*, 1978, 1641;
 (b) B. A. Teicher, N. Koizumi, M. Koreeda, M. Shikita and P. Talalay, *Eur. J. Biochem.*, 1978, 91, 11.
- 12 D. J. Vanderah and C. J. Djerassi, J. Org. Chem., 1978, 43, 1442.
- 13 (a) J. P. Marino and H. Abe, J. Am. Chem. Soc., 1981, 103, 2907;
 (b) T. Takahashi, Y. Naito and J. Tsuji, J. Am. Chem. Soc., 1981, 103, 5261;
 (c) M. Tanabe and K. Hayashi, J. Am. Chem. Soc., 1980, 102, 862.
 14 G. E. DuBois, J. Org. Chem., 1982, 47, 5035.
- 15 (a) R. Goto, M. Morisaki and N. Ikekawa, Chem. Pharm. Bull., 1983, 31, 3528; (b) W. Sucrow and M. V. Nooy, Liebigs Ann. Chem., 1982, 1897.
- 16 (a) B. G. Hazra, P. L. Joshi, B. B. Bahule, N. P. Argade, V. S. Pore and M. D. Chordia, *Tetrahedron*, 1994, **50**, 2523 and references cited therein; (b) B. G. Hazra, S. Basu, B. B. Bahule, V. S. Pore, B. N. Vyas and V. M. Ramraj, *Tetrahedron*, 1997, **53**, 4909 and references cited therein.
- 17 D. J. Aberhart and C-T. Hsu, J. Org. Chem., 1978, 43, 4374.
- 18 R. E. Marker, R. B. Wagner, P. R. Ulshafer, E. L. Wittbecker, D. P. J. Goldsmith and C. H. Rouf, J. Am. Chem. Soc., 1947, 69, 2167.
- 19 (a) H. V. Lettre, J. Greener, K. Rutz, L. Hoffmann, A. Egle and W. Bieger, *Justis Liebigs Ann. Chem.*, 1972, **758**, 89; (b) M. Koreeda, N. Koizumi and B. A. Teicher, *Chem. Commun.*, 1976, 1035.
- 20 J. M. Mellor, S. R. Schofield and S. R. Korn, *Tetrahedron*, 1997, 53, 17151.
- 21 Attempted ionic hydrogenation of compound **10** resulted in deprotection of the 3 β -TBDMS group. Deprotection of the 3 β -TBDMS group of **10** (n-Bu₄NF in THF at 25 °C, 12 h) followed by acetylation of the 3 β -OH group of compound **11** (Ac₂O, catalytic amount of DMAP in pyridine at 30 °C for 3 h) furnished the 3 β -acetate **12** in 86% overall yield in two steps.
- 22 F. A. Carey and A. Court, J. Org. Chem., 1972, 37, 1926.
- 23 C. K. Johnson, ORTEP II, report ORNL-5138, Oak Ridge National Laboratory, TN, USA (1976). (Incorporated in SHELX TL package (from Bruker-axs).
- 24 N. F. Langille, L. A. Dakin and J. S. Panek, Org. Lett., 2003, 5, 575.